| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2020-07-01 |
| タイトル |
|
|
タイトル |
Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201) |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
主題Scheme |
Other |
|
主題 |
pemetrexed |
| キーワード |
|
|
主題Scheme |
Other |
|
主題 |
bevacizumab |
| キーワード |
|
|
主題Scheme |
Other |
|
主題 |
lung cancer |
| キーワード |
|
|
主題Scheme |
Other |
|
主題 |
elderly |
| キーワード |
|
|
主題Scheme |
Other |
|
主題 |
NSqNSCLC |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 著者 |
Fukuda, Minoru
Kitazaki, Takeshi
Ogawara, Daiki
Ichiki, Masao
Mukae, Hiroshi
Maruyama, Riichiroh
Nakagaki, Noriaki
Shimada, Midori
Ikeda, Takaya
Kishimoto, Junji
Harada, Taishi
Seto, Takashi
Ebi, Noriyuki
Takayama, Koichi
Okamoto, Isamu
Ichinose, Yukito
Sugio, Kenji
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Objectives: To evaluate the efficacy and safety, we conducted a randomized phase II study of pemetrexed (Pem) versus Pem + bevacizumab (Bev) for elderly patients
with non-squamous non-small cell lung cancer (NSqNSCLC). Patients and methods: The eligibility criteria were as follows: NSqNSCLC, no prior therapy,stage IIIB/IV disease or postoperative recurrence, age: ?75 years, performance status (PS): 0?1, and adequate bone marrow function. The patients were randomly assigned (1:1 ratio)to receive Pem or Pem + Bev. The primary endpoint was progression-free survival (PFS).The secondary endpoints were the response rate, OS, toxicities, and cost-effectiveness.
Results: Forty-one patients were enrolled and 40 (20 from each group) were assessable.
Their characteristics were as follows: male/female = 23/17; median age (range) = 78 (75?83); stage IIIB/IV/postoperative recurrence = 1/30/9; PS 0/1 = 11/29. All cases involved adenocarcinoma.There was no significant intergroup difference in PFS and the median PFS (95% confidence interval)
values of the Pem and Pem + Bev groups were 5.4 (3.0?7.4) and 5.5 (3.6?9.9) months, respectively (p = 0.66). The response rate was significantly higher in the Pem + Bev group(15% vs. 55%, p = 0.0146), and there was no significant difference in OS (median: 16.0 vs. 16.4 months, p = 0.58). Grade 3 and 4 leukopenia, neutropenia,and thrombocytopenia were seen in 10 and 30, 20 and 55, and 5 and 5 cases, respectively.
Drug costs were higher in the Pem + Bev group (median: 1,522,008 vs. 3,368,428 JPY, p = 0.01). No treatment-related deaths occurred. Conclusions: Adding Bev to Pem did not result in improved survival in the elderly NSqNSCLC patients. Compared with Pem + Bev, Pem monotherapy had similar effects on survival, a more favorable toxicity profile, and was more cost-effective in elderly NSqNSCLC patients. Pem monotherapy might be one of the optional regimen for NSqNSCLC patients aged ?75 years. |
| 書誌情報 |
Lung Cancer
巻 132,
p. 1-8,
発行日 2019-06
|
| 出版者 |
|
|
出版者 |
Elsevier B.V. |
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
01695002 |
| DOI |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.1016/j.lungcan.2019.01.008 |
| 権利 |
|
|
権利情報 |
c 2019 Elsevier B.V. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| 著者版フラグ |
|
|
出版タイプ |
AM |
|
出版タイプResource |
http://purl.org/coar/version/c_ab4af688f83e57aa |
| 引用 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
Lung Cancer, 132, pp.1-8; 2019 |
LC132_1.pdf (555.7 kB)
